Wall Street Wire
Moderna's cancer vaccine with Keytruda just worked. That's huge: the stock nearly tripled, and the whole biotech index moved. As attention around oncology innovators increases, several other companies are doing exciting things that may be worth watching.
Wall Street Wire
Ten of the most followed names in biotech investing funded Entera Bio two weeks ago through its pivotal trial of EB613. Understanding the potential these investors see in Entera requires understanding the Company’s lead asset and how it could transform the way osteoporosis patients are treated.
Wall Street Wire
Medication errors cost the world an estimated $42 billion a year. Seegnal is tackling the problem with a smarter, patient-specific alert system already used by roughly 15,000 clinicians—and now the company is testing its approach in the U.S.
Biotechnology
Merck's $31.7 billion oncology drug has transformed oncology, but combining immunotherapy with radiation remains a major challenge. Tomorrow, Alpha Tau will present the first prospective data testing whether its targeted alpha radiation can change that equation.
Biotechnology
Nuvectis Pharma (NASDAQ: NVCT) just joined Lilly, AbbVie, and Merck as a Haisco in-licensor, acquiring ex-China rights to two late-stage assets for $40M upfront and up to $1.42B in milestones - a PNH drug with 7x superiority over Soliris in Phase 3, and a next-gen BRAF inhibitor for $20B+ markets.
Biotechnology
Rhythm’s latest rare-obesity win strengthens the MC4R thesis - making Palatin’s more selective, next-generation approach one of the small-cap biotech stories to watch
Biotechnology
MediWound Ltd. (Nasdaq: MDWD) recently earned a spot in one of Europe's most exclusive health security forums, and the timing could not be more relevant.